Krystal Biotech Stock
Price
Target price
€201.20
€201.20
5.350%
10.2
5.350%
€206.76
05.12.25 / Tradegate
WKN: A2JH2F / Symbol: KRYS / Name: Krystal Biotech / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Krystal Biotech Stock
Krystal Biotech dominated the market today, gaining €10.20 (5.350%).
With 23 Buy predictions and not a single Sell prediction Krystal Biotech is an absolute favorite of our community.
As a result the target price of 206 € shows a slightly positive potential of 2.39% compared to the current price of 201.2 € for Krystal Biotech.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Krystal Biotech stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Krystal Biotech in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Krystal Biotech vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Krystal Biotech | 5.350% | 6.399% | 15.665% | 18.562% | 32.194% | 164.737% | - |
| Ardelyx Inc. | -0.470% | 1.501% | -0.696% | -1.154% | 3.525% | 187.536% | -1.306% |
| Evolus Inc | 0.890% | -5.042% | -1.739% | -52.521% | -46.190% | -16.296% | 86.346% |
| Champions Oncology Inc | -0.400% | -9.455% | -12.632% | 27.041% | 4.622% | -22.791% | -42.428% |
Comments
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Chardan Capital from $216.00 to $220.00. They now have a "buy" rating on the stock.
Show more
Ratings data for KRYS provided by MarketBeat
The comment is under review
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Bank of America Corporation from $182.00 to $255.00. They now have a "buy" rating on the stock.
Show more
Ratings data for KRYS provided by MarketBeat